Vaccinex (NASDAQ:VCNX) Stock, Quote.Headers.trade-ideas

Vaccinex

Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.

Voltas shares are up today

News

Movers

VCNX

Vaccinex shares are trading lower on Wednesday after the company announced $6.2 million in proceeds from the exercise of warrants as well as the issuance of new warrants for common stock.

What&#39;s Going On With Vaccinex Stock Wednesday?

Trump's Policies Will Boost These Sectors

Long Ideas

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

TALO

Around $3M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying

xr:d:DAFqe777JJc:2,j:3049335502123804312,t:23080311

AKAN

AMZN

DASH

GPAK

INTC

LXRX

MELI

MUFG

OPEN

OSTX

PCOR

PITA

SNAP

TEAM

TNDM

VINE

VSEE

XCUR

Why DoorDash Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket

Vaccinex Inc

Earnings

Earnings Beats

Micron Technology Q4 2024 Adj. EPS $1.18 Beats $1.13 Estimate, Sales $7.750B Beat $7.635B Estimate

Offerings

Armada Hoffler Commenced Public Offering Of 7M Shares

Whales with a lot of money to spend have taken a noticeably bullish stance on Philip Morris Intl.
Looking at options history for Philip Morris Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>) we detected 11 trades.
If we consider the specifics of each trade, it is accurate to state that 45% of the investors opened trades with bullish expectations and 27% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $114,711 and 8, calls, for a total amount of $500,215.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $70.0 to $155.0 for Philip Morris Intl over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Philip Morris Intl's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Philip Morris Intl's whale activity within a strike price range from $70.0 to $155.0 in the last 30 days. 
<h3>Philip Morris Intl 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727294532_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$41.5</td>
<td>$40.8</td>
<td>$41.5</td>
<td>$80.00</td>
<td>$141.1K</td>
<td>275</td>
<td style="text-align: right;">35</td>
</tr>
<tr>
<td>PM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$5.5</td>
<td>$5.2</td>
<td>$5.4</td>
<td>$120.00</td>
<td>$81.0K</td>
<td>2.7K</td>
<td style="text-align: right;">290</td>
</tr>
<tr>
<td>PM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$21.7</td>
<td>$21.4</td>
<td>$21.6</td>
<td>$100.00</td>
<td>$75.6K</td>
<td>725</td>
<td style="text-align: right;">128</td>
</tr>
<tr>
<td>PM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$5.5</td>
<td>$5.2</td>
<td>$5.4</td>
<td>$120.00</td>
<td>$53.4K</td>
<td>2.7K</td>
<td style="text-align: right;">139</td>
</tr>
<tr>
<td>PM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$54.0</td>
<td>$51.2</td>
<td>$51.5</td>
<td>$70.00</td>
<td>$46.3K</td>
<td>72</td>
<td style="text-align: right;">10</td>
</tr>
</tbody>
</table>

<h3>About Philip Morris Intl</h3>
Created from the international operations of Altria in 2008, Philip Morris International sells cigarettes and reduced-risk products, including heatsticks, vapes, and oral nicotine offerings primarily outside of the US. With the 2022 acquisition of Swedish Match, a leading manufacturer of traditional oral tobacco products and nicotine pouches primarily in the US and Scandinavia, PMI has not only diversified away from smokeable products but also gained a toehold into the US to sell its iQOS heatsticks.
After a thorough review of the options trading surrounding Philip Morris Intl, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Philip Morris Intl</h3>
<ul>
<li>Currently trading with a volume of 4,557,848, the PM's price is up by 0.61%, now at $121.95. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 27 days.</li>
</ul>
<h3>Expert Opinions on Philip Morris Intl</h3>
Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $131.75.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Stifel persists with their Buy rating on Philip Morris Intl, maintaining a target price of $138. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Sell rating for Philip Morris Intl, targeting a price of $105. 
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on Philip Morris Intl with a target price of $139. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Philip Morris Intl, targeting a price of $145. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Philip Morris Intl, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Philip Morris Intl Unusual Options Activity

Investors with a lot of money to spend have taken a bearish stance on Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with SCHW, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 17 uncommon options trades for Charles Schwab.
This isn't normal.
The overall sentiment of these big-money traders is split between 23% bullish and 70%, bearish.
Out of all of the special options we uncovered, 13 are puts, for a total amount of $944,461, and 4 are calls, for a total amount of $750,128.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $40.0 and $75.0 for Charles Schwab, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Charles Schwab options trades today is 4687.22 with a total volume of 19,787.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Charles Schwab's big money trades within a strike price range of $40.0 to $75.0 over the last 30 days.
<h3>Charles Schwab Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727294527_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCHW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$1.08</td>
<td>$1.05</td>
<td>$1.06</td>
<td>$75.00</td>
<td>$530.0K</td>
<td>7.3K</td>
<td>6.5K</td>
</tr>
<tr>
<td>SCHW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$1.6</td>
<td>$1.49</td>
<td>$1.6</td>
<td>$62.50</td>
<td>$159.5K</td>
<td>13.2K</td>
<td>2.9K</td>
</tr>
<tr>
<td>SCHW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$1.41</td>
<td>$1.33</td>
<td>$1.41</td>
<td>$62.50</td>
<td>$155.5K</td>
<td>13.2K</td>
<td>1.1K</td>
</tr>
<tr>
<td>SCHW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.04</td>
<td>$0.99</td>
<td>$1.02</td>
<td>$75.00</td>
<td>$153.0K</td>
<td>7.3K</td>
<td>1.5K</td>
</tr>
<tr>
<td>SCHW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$1.55</td>
<td>$1.54</td>
<td>$1.54</td>
<td>$62.50</td>
<td>$102.4K</td>
<td>13.2K</td>
<td>1.9K</td>
</tr>
</tbody>
</table>

<h3>About Charles Schwab</h3>
Charles Schwab operates in brokerage, wealth management, banking, and asset management. It runs a large network of brick-and-mortar brokerage branch offices and a well-established online investing website, and it has mobile trading capabilities. It also operates a bank and a proprietary asset-management business and offers services to independent investment advisors. Schwab is among the largest firms in the investment business, with over $8 trillion of client assets at the end of December 2023. Nearly all of its revenue is from the United States.
In light of the recent options history for Charles Schwab, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Charles Schwab's Current Market Status</h3>
<ul>
<li>With a volume of 3,206,756, the price of SCHW is down -0.78% at $64.08. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 20 days.</li>
</ul>
<h3>What The Experts Say On Charles Schwab</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $70.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo downgraded its action to Equal-Weight with a price target of $70. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Charles Schwab options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

SCHW

Looking At Charles Schwab's Recent Unusual Options Activity

Investors with a lot of money to spend have taken a bullish stance on Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with RDDT, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 9 options trades for Reddit.
This isn't normal.
The overall sentiment of these big-money traders is split between 77% bullish and 22%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $55,160, and 8, calls, for a total amount of $471,233.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $60.0 to $95.0 for Reddit over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Reddit's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Reddit's significant trades, within a strike price range of $60.0 to $95.0, over the past month.
<h3>Reddit 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727294522_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RDDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/04/24</td>
<td>$4.45</td>
<td>$4.4</td>
<td>$4.45</td>
<td>$65.00</td>
<td>$111.2K</td>
<td style="text-align: right;">626</td>
<td style="text-align: right;">521</td>
</tr>
<tr>
<td>RDDT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/04/24</td>
<td>$4.3</td>
<td>$4.2</td>
<td>$4.3</td>
<td>$65.00</td>
<td>$86.0K</td>
<td style="text-align: right;">626</td>
<td style="text-align: right;">207</td>
</tr>
<tr>
<td>RDDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/27/24</td>
<td>$1.15</td>
<td>$1.13</td>
<td>$1.13</td>
<td>$69.00</td>
<td>$63.4K</td>
<td style="text-align: right;">277</td>
<td style="text-align: right;">668</td>
</tr>
<tr>
<td>RDDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$11.9</td>
<td>$11.0</td>
<td>$11.15</td>
<td>$72.50</td>
<td>$55.7K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">52</td>
</tr>
<tr>
<td>RDDT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$10.0</td>
<td>$9.85</td>
<td>$9.85</td>
<td>$65.00</td>
<td>$55.1K</td>
<td style="text-align: right;">16</td>
<td style="text-align: right;">57</td>
</tr>
</tbody>
</table>

<h3>About Reddit</h3>
Reddit Inc is engaged in providing internet content. The company provides online services that include gaming, sports, business, crypto, television and others.
Having examined the options trading patterns of Reddit, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Reddit</h3>
<ul>
<li>Currently trading with a volume of 3,501,681, the RDDT's price is down by -0.3%, now at $66.76. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 61 days.</li>
</ul>
<h3>What Analysts Are Saying About Reddit</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $75.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from B. Riley Securities lowers its rating to Buy with a new price target of $75. 
&#x2A; An analyst from Needham downgraded its action to Buy with a price target of $75. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Reddit, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

RDDT

Looking At Reddit's Recent Unusual Options Activity

Key financial results for the first half of 2024
<figure class="table"> 
<table>
<tbody>
<tr>
<td rowspan="2">(in thousands of euros)</td>
<td colspan="3">Six months ended</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>June 30, 2024</td>
<td>&nbsp;</td>
<td>June 30, 2023</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Revenues</td>
<td>41</td>
<td>1,901</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Other income</td>
<td>2,693</td>
<td>4,721</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Research and development expenses</td>
<td>(46,822)</td>
<td>(54,062)</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Marketing – business development expenses</td>
<td>(598)</td>
<td>(705)</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>General and administrative expenses</td>
<td>(7,701)</td>
<td>(6,812)</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Other operating income (expenses)</td>
<td>138</td>
<td>(44)</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Net operating loss</td>
<td>(52,249)</td>
<td>(55,003)</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Net financial income</td>
<td>3,507</td>
<td>(273)</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Share of net loss - Equity method</td>
<td>(168)</td>
<td>0</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Income tax</td>
<td>(119)</td>
<td>7</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Net loss for the period</td>
<td>(49,029)</td>
<td>(55,269)</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Basic/diluted loss per share (euros/share)</td>
<td>(0.94)</td>
<td>(1.31)</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Weighted average number of outstanding shares used for computing basic/diluted loss per share</td>
<td>&nbsp;</td>
<td>51,982,093</td>
<td>&nbsp;</td>
<td>42,044,796</td>
</tr>
</tbody>
</table>
</figure>
The Company did not record any revenues in the first half of 2024, as compared to €1.9 million recorded during the same period in 2023. The revenues recorded by the Company in the first half of 2023 were attributed to a milestone payment by CTTQ, a Sino Biopharm subsidiary, after it received the Investigational New Drug ("IND") approval from the Chinese National Medical Products Administration ("NMPA") in May 2023, allowing the initiation of the clinical development of lanifibranor in MASH/NASH in mainland China.
Other income amounted to €2.7 million for the first half of 2024, as compared to €4.7 million for the first half of 2023, decreased 42.5% mainly driven by the reclassification in 2024 of some R&amp;D expenses reinvoiced to CTTQ that were previously recorded in other income, and to a lesser extent by the slight decrease in research tax credit due to decrease in R&amp;D expenses for the period compared to the first half of 2023.
R&amp;D expenses for the first half of 2024 amounted to €46.8 million, mainly driven by the development of lanifibranor in MASH/NASH and were down 13.4% compared to the €54.1 million for the first half of 2023. The decrease in R&amp;D expenses over the period is primarily due to the temporary voluntary pause in the recruitment of patients in the NATiV3 Phase III clinical trial of lanifibranor in MASH/NASH ("NATiV3") following the Suspected Unexpected Serious Adverse Reaction ("SUSAR") previously reported in the first quarter of 2024 and, to a lesser extent, due to the completion of the LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and type 2 diabetes ("T2D"). R&amp;D expenses are expected to increase in the second half of 2024 following the restart of patient recruitment in NATiV3, as well as the planned clinical development activities and related costs associated with the NATiV3 for the second half of 2024.
Marketing and business development expenses stood at €0.6million for the first half of 2024 compared to €0.7 million for the same period in 2023.
General and administrative expenses (G&amp;A) amounted to €7.7 million in the first half of 2024, compared to €6.8 million in the first half of 2023. Increase by 13% is mainly due to personnel costs and consulting fees.
Net financial income (loss) amounted to €3.5 million in the first half of 2024, compared to (€0.3) million. The income mainly relates to the change in fair value of the warrants issued to the European Investment Bank ("EIB") in connection with the drawdown of two tranches of €25 million under our unsecured loan agreement with EIB (the "Finance Contract"), and is partially offset by an increase in the financial interests borne on those tranches and on the royalty certificates issued in August 2023 (the "2023 Royalty Certificates").
The Company's net loss stood at (€49.0) million as of June 30, 2024, compared to (€55.3) million as of June 30, 2023.
As of June 30, 2024, the Company's cash and cash equivalents stood at €10.1 million, compared to cash and cash equivalents at €26.9 million, short-term deposits1 of €0.01million, and long-term deposits2&nbsp;of €9.0 million as of December 31, 2023.
Net cash used in operating activities amounted to (€48.3) million in the first half of 2024, compared to (€45.2) million for the same period in 2023 down by 6.8% while the R&amp;D expenses for the first half of 2024 were (€46.8) million, down 13.3% compared to the first half of 2023 (see above) partially offset by a negative working capital variance between both periods.
Net cash generated from investing activities for the first half of 2024 amounted to €8.9 million, compared to (€7.7) million used in the first half of 2023. The change is mostly due to the variation in term deposits between both periods.
Net cash generated from financing activities for the first half of 2024 amounted to €22.6 million, compared to (€2.2) million used in the first half of 2023. The change is due to the second tranche of €25 million drawn in January 2024 under the Finance Contract. As a condition to the drawdown of the second tranche, the Company issued 3,144,654 warrants to the EIB.
Over the first half of 2024, the Company recorded a positive exchange rate effect on cash and cash equivalents of €0.1 million, compared to a negative effect of (€0.4) million for the first half of 2023, due to the evolution of the EUR/USD exchange rate.

Inventiva H1 EPS €(0.94) Up From €(1.31) YoY; Revenue €41K Down From €1.9M YoY

Management

OMCL

Omnicell Names Nnamdi Njoku As Executive Vice President And COO, Effective October 7, 2024

Martin Marietta Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLM#NYSE">MLM</a>) has outperformed the market over the past 10 years by 4.13% on an annualized basis producing an average annual return of 15.33%. Currently, Martin Marietta Materials has a market capitalization of $32.97 billion. 
Buying $100 In MLM: If an investor had bought $100 of MLM stock 10 years ago, it would be worth $413.96 today based on a price of $539.51 for MLM at the time of writing.
<h3>Martin Marietta Materials's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727294428_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Martin Marietta Materials 10 Years Ago Would Be Worth This Much Today

Fiserv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) has outperformed the market over the past 10 years by 7.29% on an annualized basis producing an average annual return of 18.49%. Currently, Fiserv has a market capitalization of $102.10 billion. 
Buying $100 In FI: If an investor had bought $100 of FI stock 10 years ago, it would be worth $546.73 today based on a price of $177.35 for FI at the time of writing.
<h3>Fiserv's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727294423_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 10 Years Ago, You Would Have $500 Today

A study compared the association of semaglutide vs other antidiabetic medications and other GLP-1RAs, including liraglutide and dulaglutide, with opioid overdose risk in patients with comorbid type 2 diabetes (T2D) and opioid use disorder (OUD).
Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) semaglutide is available as Wegovy and Ozempic for weight loss and diabetes, respectively, and liraglutide is sold as Saxenda and Victoza.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41025381/exclusive-novo-nordisk-faces-political-heat-over-weight-loss-drug-prices-ahead-of-e" rel="noreferrer noopener">EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet &#8216;The Real Issue Is With The Middlemen&#8217;</a>.
Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) dulaglutide is available as Trulicity.
Drug overdose <a target="_blank" href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2824054?guestAccessKey=67ec89b0-a682-4fbf-97d9-1c0054b62d04&amp;utm_source=for_the_media&amp;utm_medium=referral&amp;utm_campaign=ftm_links&amp;utm_content=tfl&amp;utm_term=092524" rel="noreferrer noopener">deaths</a> in the U.S. remain alarmingly high, with an estimated 107,543 fatalities in 2023, primarily due to opioids.
Despite the proven effectiveness of medications for opioid use disorder (OUD) in reducing overdose risk, only about 25% of individuals with OUD receive treatment, and nearly half discontinue it within six months. This highlights the urgent need for alternative OUD therapies.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), commonly used to treat type 2 diabetes and obesity, have been shown to modulate dopamine reward pathways and reduce drug rewards, including heroin, in animal studies.
Additionally, anecdotal reports and studies have suggested that semaglutide may reduce drug cravings and offer therapeutic benefits in alcohol and nicotine use disorders.
These findings prompted an investigation into whether semaglutide could potentially help prevent overdoses in OUD patients.
Semaglutide was associated with a significantly lower risk of opioid overdose during a 1-year follow-up compared with other antidiabetic medications, including other GLP-1RAs, with HRs ranging from 0.32 to 0.58. 
The negative control outcome showed no difference between groups. The update signals a potential new use for the blockbuster diabetes medications.
The researchers noted that results need validation from other data resources and study populations. Further research is warranted to investigate the underlying mechanisms, and randomized clinical trials are necessary to corroborate the clinical effects on OUD.
The study utilized six years of data (between December 2017 and June 2023) from over 33,006 patients.
Earlier this year, a comprehensive U.S. study revealed that the use of&nbsp;Ozempic and Wegovy is not associated with an increased&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36509636/novo-nordisks-ozempic-and-wegovy-helps-lose-weight-not-ones-mind-us-study-find-no-increased-suici" rel="noreferrer noopener">risk of suicidal thoughts</a>.
Price Action: NVO stock is up 1.16% at $126.90, and LLY stock is down 0.05% at $924.01 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41031132/amgens-rocatinlimab-has-commercial-potential-despite-competitive-landscape-says-gol" target="_blank" rel="noreferrer noopener">Amgen&#8217;s Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs</a>.</li>
</ul>
Image via Shutterstock

Biotech

Large Cap

Health Care

General

Popular Ozempic May Have New Use As Semaglutide Drugs Linked To Reduced Overdose Risk In Diabetic Opioid Users

The FBI reported that 217,150 arrests for marijuana violations were made in 2023, slightly down from 2022 when the figure stood at 227,108, according to data <a href="https://www.fbi.gov/news/press-releases/fbi-releases-2023-crime-in-the-nation-statistics">published</a> in the Bureau&#8217;s Crime Data Explorer.
Of those arrested in 2023, a staggering 84%—a bit over 200,000 people—were charged with possession alone, highlighting the ongoing focus on low-level cannabis offenses. It's important to note that the FBI's arrest data reflects the number of arrests, not the number of individuals arrested, as a person may be arrested multiple times in a year.
The 2023 figures are based on reports from local agencies covering 90 percent of the U.S. population, meaning the true number of marijuana arrests is <a href="https://www.benzinga.com/markets/cannabis/22/06/27495845/why-fbis-count-on-marijuana-arrests-may-be-wrong-doj-urged-to-investigate-on-inconsistent-statis">likely higher</a>.
While this represents a long-term decline from the peak of 870,000 marijuana-related arrests in 2007, deputy director of the National Organization for the Reform of Marijuana Laws <a href="https://www.benzinga.com/topic/norml">(NORML),</a>  Paul Armentano <a href="https://norml.org/blog/2024/09/25/fbi-nearly-one-quarter-of-all-drug-related-arrests-are-for-marijuana-possession/">expressed</a> concern.
"At a time when voters and their elected officials nationwide are re-evaluating state and federal marijuana policies, it is inconceivable that government agencies are unable to produce more explicit data on the estimated costs and scope of marijuana prohibition in America," Armentano said.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Marijuana Possession Dominates Arrest Rates</h3>
Despite state legalization efforts, marijuana-related prosecutions remain a major driver of the U.S. drug war.
Marijuana arrests are part of a larger trend of drug possession offenses, which ranked second for arrest offense rates in the United States in 2023. Police recorded 3,801,505 cases of drug possession, following only the category of &#8220;All Other Offenses.&#8221;
Drug possession was followed by arrests for simple assault (3,584,195 cases), driving under the influence (2,863,542 cases), and larceny (2,372,550 cases). Data follows a <a href="https://www.benzinga.com/markets/cannabis/22/10/29161642/fbi-crime-report-cannabis-busts-still-favorite-pastime-of-nations-cops-though-experts-say-data-i">trend</a> that&#8217;s been present in every other report in the past. 
Aggravated assault was further down the list, underscoring how low-level drug offenses still dominate the U.S. criminal justice system.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/06/39277643/legal-weed-less-crime-fbi-data-shows-surprising-benefits-of-cannabis-legalization">Legal Weed = Less Crime: FBI Data Shows Surprising Benefits Of Cannabis Legalization</a>
<h3 class="wp-block-heading">2023 FBI Data Overview</h3>
The FBI 2023 Crime in the Nation statistics, details over 14 million criminal offenses reported by more than 16,000 law enforcement agencies.
This data seeks to represent 94.3% of the U.S. population. One main outcome is that in 2023, national violent crime decreased by 3.0%, with notable reductions in murder, rape, aggravated assault and robbery. The agency also tracked a slight 0.6% decline in hate crime incidents, signaling progress in multiple areas of law enforcement, even as marijuana arrests continue to contribute significantly to the numbers.
Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/06/39229569/gop-sen-collins-grills-fbi-on-serious-problem-of-chinese-organized-crime-in-illegal-cannabis-cul">GOP Sen. Collins Grills FBI On &#8216;Serious Problem&#8217; Of Chinese Organized Crime In Illegal Cannabis Cultivation In Maine</a>
Cover: FBI Media website

Cannabis

Government

Regulations

Politics

Economics

FBI Report Over 200,000 People Were Arrested For Cannabis-Related Violations In 2023: How Is That Possible?

A threat to impose a 200% tariff on John Deere products by former President Donald Trump could hurt publicly traded Deere &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) and the investors who hold the stock, including <a href="https://www.benzinga.com/general/politics/24/05/39096827/exclusive-khanna-says-shameful-congress-members-profited-from-stocks-calls-for-trading-ban-makin">members of Congress</a>.
What Happened: Trump recently said he <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41022098/experts-slam-trumps-200-tariff-threat-to-john-deere-youll-find-no-serious-respected">would place a hefty tariff </a>on John Deere products if the company shifts some production from the U.S. to Mexico.
"If you do that, we're putting a 200% tariff on everything that you want to sell into the United States," Trump said at a Pennsylvania event.
The threat from Trump could have a major impact on Deere's future growth plans as it looks for new ways to cut costs and increase production.
A tariff could hurt the stock price and investors, which includes several members of Congress.
According to<a href="https://www.benzinga.com/gov-trades/securities/DE"> Benzinga's Government Trades page,</a> Representatives Rick Allen (R-Ga.) and Josh Gottheimer (D-N.J.) sold their Deere stock in August and June respectively. While the sales were likely done for various reasons, concerns over a potential tariff could be a consideration for ditching the stock.
One Congress member who has been buying Deere stock is Senator Markwayne Mullin (R-Okla.).
Mullin disclosed buying $1,000 to $15,000 in DE stock in October 2023 and $15,000 to $50,000 in DE stock in September 2023.
The potentially harmful impact on Deere with tariffs or threats of tariffs could hurt Mullin's portfolio. Mullin <a href="https://www.foxnews.com/politics/oklahoma-sen-markwayne-mullin-endorses-trump-president-2024">endorsed </a>Trump for president in the 2024 election last year. Trump previously endorsed Mullin during his 2022 Senate election campaign.
Did You Know? Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent092524">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a>
Why It's Important: Trump's comments come as he has threatened to impose tariffs on companies that move production to other countries like Mexico and China.
The threat against John Deere <a href="https://www.benzinga.com/news/24/09/40993998/mark-cuban-says-trumps-lack-of-understanding-business-is-insane-slams-200-tariff-threat-on-john-deer">caught the attention</a> of billionaire entrepreneur Mark Cuban.
"This lack of understanding of business is insane," Cuban said. "Put a 200% tariff on the American company moving some production to Mexico but tariff Chinese manufacturers 10% or 20%, so that the Chinese products will be cheaper to sell in the U.S. than the American company."
Cuban said the threat and follow-through would be a "good way to destroy a legendary American company."
A return of Trump to the White House could increase pressure on companies with overseas production, potentially leading to the imposition of tariffs.
DE Price Action: Deere shares traded at $407.40 on Wednesday, versus a 52-week trading range of $340.20 to $417.47. Deere stock is up 1.4% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40393005/deere-q3-earnings-profit-beats-expectations-despite-sales-drop-reaffirms-annual-net-income-outlook">Deere Q3 Earnings: Profit Beats Expectations Despite Sales Drop, Reaffirms Annual Net Income Outlook</a></li>
</ul>
Photo: Shutterstock

Trump's Tariff Threat Could Hit John Deere Stock: Pro-Trump Congress Member Faces Potential Losses

On Thursday, 26 September, the FDA's Oncologic Drugs Advisory Committee will discuss the use of immune checkpoint inhibitors in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma and esophageal <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40534057/cancer-medicines-from-merck-bristol-myers-and-beigene-in-question-as-fda-committee-to-discuss-lim" rel="noreferrer noopener">squamous cell carcinoma</a>.
The FDA <a target="_blank" href="https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-26-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-09262024" rel="noreferrer noopener">notes</a> that the current labeling for approved checkpoint inhibitors in this indication reflects broad approvals in the intent to treat patient populations agnostic of programmed death cell ligand-1 (PD-L1) expression.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40534057/cancer-medicines-from-merck-bristol-myers-and-beigene-in-question-as-fda-committee-to-discuss-lim" rel="noreferrer noopener">Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer</a>.
Cumulative data has shown that PD-L1 expression appears to be a predictive biomarker of treatment efficacy in this patient population; however, clinical trials have used different approaches to assess PD-L1 expression and different thresholds to define PD-L1 positivity.
The review includes existing approvals for&nbsp;Bristol Myers Squibb Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)&nbsp;Opdivo (nivolumab) and Yervoy (ipilimumab),&nbsp;Merck &amp; Co Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)&nbsp;Keytruda (pembrolizumab), and pending applications for&nbsp;BeiGene Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGNE#NASDAQ">BGNE</a>)&nbsp;Tevimbra (tislelizumab).
In a&nbsp;<a target="_blank" href="https://www.fda.gov/media/182138/download" rel="noreferrer noopener">briefing document</a>, the FDA indicated that combining immune checkpoint inhibitors (ICIs) with standard chemotherapy does not seem to offer benefits for patients with PD-L1 expression below 1%. Patients with PD-L1 levels of 10% or higher experience the most significant benefit.
The advantages remain unclear for those with PD-L1 levels between 1% and 10%, and interpreting the data is difficult.
Given that patients with low or absent PD-L1 expression are unlikely to benefit, administering anti-PD-1 therapy may introduce risks, including severe immune-related adverse effects, which can further diminish the quality of life in individuals already dealing with malignancy.
"Although these results are exploratory &#8230; strong evidence does not appear to support the use of anti-PD-L1 drugs in patients with low PD-L1 expression," the FDA <a target="_blank" href="https://www.fda.gov/media/182143/download" rel="noreferrer noopener">said</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41028913/bristol-myers-2seventy-bio-halt-phase-3-trial-for-abecma-in-newly-diagnosed-myeloma" target="_blank" rel="noreferrer noopener">Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability</a>.</li>
</ul>
Image by PDPics from Pixabay

BGNE

FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients

VRTX

Health Canada Approves CASGEVY (Exagamglogene Autotemcel), The First CRISPR/Cas9 Gene-Edited Therapy, For Treatment Of Sickle Cell Disease And Transfusion-Dependent Beta Thalassemia In Patients 12 And Older

WIIM

Southwest Airlines shares are trading lower following a report suggesting the company will reduce service and staffing in Atlanta.

Last week, Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) released topline data on Monday from a trial that included 84 children with achondroplasia, a genetic disorder that causes dwarfism and&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40882593/ascendis-pharmas-rare-dwarfism-candidate-shows-promise-in-trial-fda-submission-expected-next-year" rel="noreferrer noopener">disproportionate short stature</a>.
Goldman Sachs hosted an investor meeting with BioMarin Pharmaceutical Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) Alexander Hardy (President and CEO) and Brian Mueller (EVP, CFO).
They reiterated financial guidance after reviewing their assumptions around Voxzogo competition post-Ascendis Pharma's better-than-expected Phase 3 achondroplasia data.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40200109/rare-disease-focused-biomarin-narrows-sales-focus-cuts-cost-for-hemophilia-a-gene-t" rel="noreferrer noopener">Rare Disease-Focused BioMarin Narrows Sales Focus, Cuts Cost For Hemophilia A Gene Therapy; Lifts Annual Guidance</a>.
The analyst notes that management believes a U.S./EU launch by Ascendis Pharma could violate its C-type natriuretic <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40885653/despite-being-first-mover-biomarins-voxzogo-for-dwarfism-to-face-pressure-from-asce" rel="noreferrer noopener">peptide (CNP) patents</a>.
However, excluding this concern, the company still expects to reach approximately $4 billion in total revenue for fiscal year 2027, driven by growing Voxzogo adoption in the U.S., aided by its broad label without lower age restrictions, which could provide a competitive edge over Ascendis Pharma.
The company is targeting an adjusted operating margin of low-to-mid 40% (starting at 40% in 2026).
The new structure, announced at an investor event,&nbsp;<a target="_blank" href="https://investorday.biomarin.com/static-files/95c517e2-36ee-4427-9278-2d87cc4c1460" rel="noreferrer noopener">covers</a> three key business units: skeletal conditions, enzyme therapies, and Roctavian—its <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40731810/biomarin-restructures-outlines-roadmap-to-4b-revenues-by-2027" rel="noreferrer noopener">hemophilia A gene therapy</a>.
BioMarin has been implementing a $500 million "cost transformation program"&nbsp;to contribute to non-GAAP operating margin targets set for 2026 and beyond.
Goldman Analyst writes, "We also see external business development as a potential source of upside and diversification beyond BioMarin's guidance. Nonetheless, we note continued investor debate on the outlook given increasing competitive pressure on BioMarin's key growth driver."
The analyst maintains a Buy rating with a <a target="_blank" href="https://www.benzinga.com/quote/BMRN/analyst-ratings" rel="noreferrer noopener">price target of $139</a>.
Price Action: BMRN stock is down 0.57% at $69.09 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41029168/meta-connect-leaks-reveal-affordable-quest-3s-batman-game-bundle-report" target="_blank" rel="noreferrer noopener">Meta Connect Leaks Reveal Affordable Quest 3S, Batman Game Bundle: Report</a>.</li>
</ul>

Analyst Color

Analyst Ratings

ASND

BMRN

BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish

SAP shares are trading lower amid reports of the DOJ investigating the company and Carahsoft for alleged price fixing.

ServiceNow shares are trading lower. The stock may be under pressure following the DOJ's Carahsoft investigation.

Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) shares are trading higher Wednesday as investors react to AI, virtual reality (VR) and augmented reality (AR) announcements made during the company&#8217;s <a href="https://www.benzinga.com/news/24/09/41032461/meta-unveils-new-ai-features-quest-3s-llama-3-2-holographic-orion-glasses-at-connect-2024-we-are-get">&#8216;Meta Connect 2024&#8217; event. </a>
What To Know: Key highlights from the event include the unveiling of Meta&#8217;s Quest 3S, a mixed-reality headset priced at $299, which will start shipping on October 15 2024. The company also revealed updates to its Ray-Ban Meta smart glasses, now featuring AI-driven tools like reminders, QR code scanning and future capabilities such as live translation between multiple languages. 
Additionally, Meta introduced its &#8216;Orion&#8217; AR glasses, a prototype product that runs its Meta AI assistant, which will soon be tested by select audiences.
Meta's push toward AI continues to gain momentum, with the company announcing that its Meta AI chatbot is used by more than 400 million people monthly. Meta also plans to expand its AI tools for businesses, particularly those using click-to-message ads on Messenger and WhatsApp. Furthermore, the company is enhancing its generative AI ad tools and released the Llama 3.2 AI models, capable of understanding both text and images.
META price Action: Meta shares were up by 1.42% at $571.36 according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1722883001180099"><img loading="lazy" decoding="async" width="1024" height="580" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25143059/META-1-1024x580.png" alt="" class="wp-image-566263" style="width:418px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25143059/META-1-1024x580.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25143059/META-1-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25143059/META-1-768x435.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25143059/META-1.png 1075w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/41032446/nano-dimension-snaps-up-markforged-in-115m-deal-details">Nano Dimension Snaps Up Markforged In $115M Deal: Details</a></li>
</ul>
Image Via Shutterstock.

Why Meta Shares Are Trading Higher Today

Palworld, the open-world crafting game often described as "Pokémon with guns", surprise-launched on the PlayStation 5 on Sept. 24, following Sony Group Corp.&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) <a href="https://www.benzinga.com/general/gaming/24/09/41030256/playstation-plus-october-lineup-revealed-wwe-2k24-dead-space-more">State of Play broadcast. </a>
Gamers from 68 countries eagerly downloaded the long-awaited release, but fans in Japan were left in the dark. Despite the global excitement, Japanese players found themselves unable to access the game.
See Also: <a href="https://www.benzinga.com/general/gaming/24/09/40962380/nintendos-killer-patent-could-crush-palworlds-monster-catching-gameplay-expert-warns">Nintendo&#8217;s &#8216;Killer Patent&#8217; Could Crush Palworld&#8217;s Monster-Catching Gameplay, Expert Warns</a>
<h3 class="wp-block-heading">Palworld PS5 Block In Japan</h3>
Pocketpair, the Japanese developer behind Palworld, took to X (formerly Twitter) to address the situation. The official Japanese Palworld account confirmed that the PS5 release in Japan "has not yet been decided," offering no further explanation for the delay. 
&#8220;We apologize to everyone in Japan who was looking forward to it, but all of our staff will do our best to deliver it to PS5 users as soon as possible, so we hope you will wait for a little longer. We look forward to your continued support of Palworld.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">＜PS5版『Palworld / パルワールド』について＞ PlayStation公式『State of Play』にて発表があった通り、PS5版『Palworld / パルワールド』が本日、全世界68の国と地域で発売されました。… <a href="https://t.co/BNzS18XBYK">https://t.co/BNzS18XBYK</a>
&mdash; パルワールド/Palworld 公式 (@Palworld_JP) <a href="https://twitter.com/Palworld_JP/status/1838716479136763971?ref_src=twsrc%5Etfw">September 24, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The developer stopped short of specifying the reason behind the delay. But many suspect it is linked to a recent lawsuit filed by Nintendo ADR (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NTDOY#OTC">NTDOY</a>) and The Pokémon Company against Pocketpair. The case, which was filed in the Tokyo District Court, accuses the developer of infringing on Pokémon-related patents.
<h3 class="wp-block-heading">The Legal Battle: Pokémon Vs. Palworld</h3>
Industry insiders believe that the legal dispute centers around a "killer patent" tied to the mechanics of catching creatures—a key gameplay feature in both Pokémon and Palworld. 
In Palworld, players can capture creatures using a ball-like object called a Pal Sphere, a concept that is strikingly similar to the capturing mechanic seen in Pokémon Legends: Arceus.
Pocketpair responded to the lawsuit with a public statement, claiming they were unaware of the specific patents they allegedly infringed upon. 
For now, Palworld remains available on all previously supported platforms, including Xbox and PC via Steam. The game is also still part of Microsoft&#8217;s Game Pass subscription service. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/03/37755269/palworld-success-overwhelms-too-big-for-our-studio-but-pocketpair-open-to-acquisitions">Palworld&#8217; Success Overwhelms: &#8216;Too Big for Our Studio,&#8217; But Pocketpair Open To Acquisitions</a></li>
</ul>
Image credits: Shutterstock.

Gaming

NTDOY

Sony Group Corporation American Depositary Shares

SONY

Palworld Launches On PS5, But Why Can't Japan Play?

Vaccinex (VCNX) has issued an update. Vaccinex, Inc. has announced the completion of the final patient visit in its SIGNAL-AD Phase 1b/2 study, eva...

Vaccinex Completes Key Study Phase for Alzheimer's Drug

Vaccinex files to sell 490,509 shares of common stock for holders

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth diving into as we check out all of the hottest news affecting shares on Monday morning!



Moving stocks this morning are clinical trial updates, an acquisition deal and a public offering.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Planet Image (NASDAQ:<a href="https://investorplace.com/stock-quotes/yibo-stock-quote/">YIBO</a>) stock is rocketing more than 79% alongside heavy pre-market trading.</li>



<li>Lipella Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/lipo-stock-quote/">LIPO</a>) shares are soaring over 58% after <a href="https://www.stocktitan.net/news/LIPO/lipella-pharmaceuticals-initiates-phase-2a-trial-for-lp-310-in-oral-kdvluw7gmnv7.html">initiating a Phase 2a clinical trial</a>.</li>



<li>Cognition Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cgtx-stock-quote/">CGTX</a>) stock is surging more than 44% with <a href="https://www.nasdaq.com/press-release/cognition-therapeutics-proof-concept-phase-2-shine-trial-demonstrates-consistent">positive Phase 2 study results</a>.</li>



<li>Tivic Health Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/tivc-stock-quote/">TIVC</a>) shares are gaining over 32% following a <a href="https://www.nasdaq.com/press-release/bestgrowthstockscom-issues-comprehensive-analysis-tivic-health-systems-potential">breakdown of its potential catalysts</a>.</li>



<li>Longeveron (NASDAQ:<a href="https://investorplace.com/stock-quotes/lgvn-stock-quote/">LGVN</a>) stock is increasing more than 22% with the release of <a href="https://www.nasdaq.com/press-release/longeveronr-presents-study-results-clear-mind-phase-2a-clinical-trial-lomecel-btm">Phase 2a study results</a>.</li>



<li>Pineapple Financial (NYSEMKT:<a href="https://investorplace.com/stock-quotes/papl-stock-quote/">PAPL</a>) shares are rising 22% without any clear news this morning.</li>



<li>Cepton (NASDAQ:<a href="https://investorplace.com/stock-quotes/cptn-stock-quote/">CPTN</a>) stock is climbing over 19% on <a href="https://www.stocktitan.net/news/CPTN/cepton-signs-definitive-agreement-to-be-acquired-by-7cwu0k4o8p93.html">an acquisition agreement</a>.</li>



<li>Ambipar Emergency (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ambi-stock-quote/">AMBI</a>) shares are jumping more than 18% this morning.</li>



<li>BurgerFi (NASDAQ:<a href="https://investorplace.com/stock-quotes/bfi-stock-quote/">BFI</a>) stock is heading over 16% higher as it <a href="https://investorplace.com/2024/07/why-is-burgerfi-international-bfi-stock-up-71-today/">continues a recent rally</a>.</li>



<li>Vaccinex (NASDAQ:<a href="https://investorplace.com/stock-quotes/vcnx-stock-quote/">VCNX</a>) shares are up more than 15% this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>vTv Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/vtvt-stock-quote/">VTVT</a>) stock is plummeting over 44% after announcing the Food and Drug Administration&nbsp;(FDA) <a href="https://www.nasdaq.com/press-release/vtv-therapeutics-announces-cadisegliatin-program-type-1-diabetes-placed-clinical-hold">placed a clinical hold</a> on one of its trials.</li>



<li>CERo Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cero-stock-quote/">CERO</a>) shares are diving more than 33% despite a lack of news this morning.</li>



<li>Treasure Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/tgl-stock-quote/">TGL</a>) stock is tumbling over 25% on Monday morning.</li>



<li>LuxUrban Hotels (NASDAQ:<a href="https://investorplace.com/stock-quotes/luxh-stock-quote/">LUXH</a>) shares are taking a more than 17% beating after <a href="https://www.globenewswire.com/news-release/2024/07/27/2919920/0/en/LuxUrban-Hotels-Announces-Pricing-of-Public-Offering-of-Securities.html">pricing a public offering</a>.</li>



<li>Invo Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/invo-stock-quote/">INVO</a>) stock is dropping over 11% without any clear news to report.</li>



<li>Phio Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/phio-stock-quote/">PHIO</a>) shares are sliding more than 11% this morning.</li>



<li>Notable Labs (NASDAQ:<a href="https://investorplace.com/stock-quotes/ntbl-stock-quote/">NTBL</a>) stock is decreasing over 10% on Monday morning.</li>



<li>Regencell Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgc-stock-quote/">RGC</a>) shares are falling more than 9% after a Friday rally.</li>



<li>Carbon Revolution (NASDAQ:<a href="https://investorplace.com/stock-quotes/crev-stock-quote/">CREV</a>) stock is slipping over 9% after jumping Friday <a href="https://finance.yahoo.com/news/carbon-revolution-supplies-carbon-fiber-011000695.html">on a wheels deal</a>.</li>



<li>Nuwellis (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuwe-stock-quote/">NUWE</a>) shares close out our pre-market stock movers down more than 9%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-july-29th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Vaccinex stock plunges 24% on mixed results for Alzheimer's study

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start off the final trading day of the week with a breakdown of the biggest pre-market stock movers for Friday morning!



Moving stocks this morning are earnings reports, a failed merger deal, delisting updates and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>VSee Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsee-stock-quote/">VSEE</a>) stock is rocketing more than 159% as the robot maker <a href="https://www.nasdaq.com/press-release/vsee-health-and-ava-robotics-partner-develop-telepresence-solutions-hospital">plans for telepresence solutions</a> for the inpatient intensive care market.</li>



<li>Adagio Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/adgm-stock-quote/">ADGM</a>) shares are soaring close to 36% following its <a href="https://www.businesswire.com/news/home/20240731222906/en/Adagio-Medical-Announces-the-Closing-of-the-Business-Combination-with-ARYA-IV-Creating-a-Publicly-Traded-Company-Focused-on-the-Innovative-Technologies-for-Treatment-of-Cardiac-Arrhythmias">recent public debut</a>.</li>



<li>Akanda (NASDAQ:<a href="https://investorplace.com/stock-quotes/akan-stock-quote/">AKAN</a>) stock is surging over 35% alongside heavy pre-market trading.</li>



<li>Exicure (NASDAQ:<a href="https://investorplace.com/stock-quotes/xcur-stock-quote/">XCUR</a>) shares are gaining more than 29% on a <a href="https://www.businesswire.com/news/home/20240801299565/en/Exicure-Inc.-Receives-Positive-Listing-Determination-from-Nasdaq">positive listing update</a> from the Nasdaq Capital Market.</li>



<li>Australian Oilseeds (NASDAQ:<a href="https://investorplace.com/stock-quotes/coot-stock-quote/">COOT</a>) stock is rising 25% after announcing a <a href="https://www.nasdaq.com/press-release/australian-oilseeds-announces-appointment-new-independent-auditor-2024-08-01">new independent auditor</a>.</li>



<li>Tandem Diabetes Care (NASDAQ:<a href="https://investorplace.com/stock-quotes/tndm-stock-quote/">TNDM</a>) shares are increasing nearly 25% with the release of its <a href="https://www.nasdaq.com/press-release/tandem-diabetes-care-announces-second-quarter-2024-financial-results-and-increases">Q2 earnings report</a>.</li>



<li>Vaccinex (NASDAQ:<a href="https://investorplace.com/stock-quotes/vcnx-stock-quote/">VCNX</a>) stock is heading over 23% higher with <a href="https://www.nasdaq.com/press-release/vaccinex-reports-positive-data-signal-ad-phase-1b-2-trial-pepinemab-alzheimers">recent clinical trial news</a>.</li>



<li>AGBA Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/agba-stock-quote/">AGBA</a>) shares are climbing more than 13% without any clear news this morning.</li>



<li>Venus Concept (NASDAQ:<a href="https://investorplace.com/stock-quotes/vero-stock-quote/">VERO</a>) stock is jumping over 13% on Friday morning.</li>



<li>Integral Ad Science (NASDAQ:<a href="https://investorplace.com/stock-quotes/ias-stock-quote/">IAS</a>) shares are up 13% with its <a href="https://www.nasdaq.com/press-release/ias-reports-second-quarter-2024-financial-results-2024-08-01">latest earnings news</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Gamer Pakistan (NASDAQ:<a href="https://investorplace.com/stock-quotes/gpak-stock-quote/">GPAK</a>) stock is plummeting almost 47% <a href="https://www.pr.com/press-release/917157#:~:text=(Nasdaq%3AGPAK)%20(GPAK,and%20that%20trading%20of%20the">alongside a delisting notice</a>.</li>



<li>Fresh Vine Wine (NYSEMKT:<a href="https://investorplace.com/stock-quotes/vine-stock-quote/">VINE</a>) shares are diving more than 37% with the <a href="https://www.nasdaq.com/press-release/fresh-vine-wine-inc-and-notes-live-inc-mutually-agree-terminate-merger-agreement-2024">termination of a merger agreement</a>.</li>



<li>Conn&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/conn-stock-quote/">CONN</a>) stock is tumbling over 30% as Badcock Home Furniture &amp; More <a href="https://nypost.com/2024/08/01/business/major-furniture-chain-badcock-to-shut-all-its-stores-after-120-years/">shuts down all of its stores</a>.</li>



<li>Greenlane (NASDAQ:<a href="https://investorplace.com/stock-quotes/gnln-stock-quote/">GNLN</a>) shares are taking a more than 24% beating on plans for a <a href="https://www.stocktitan.net/news/GNLN/greenlane-announces-board-s-approval-of-reverse-stock-split-9yehmvs5r4ed.html">reverse stock split</a>.</li>



<li>Procore Technologies (NYSE:<a href="https://investorplace.com/stock-quotes/pcor-stock-quote/">PCOR</a>) stock is dropping 22% alongside its <a href="https://www.nasdaq.com/press-release/procore-announces-second-quarter-2024-financial-results-2024-08-01">Q2 earnings report</a>.</li>



<li>Estrella Immunopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/esla-stock-quote/">ESLA</a>) shares are sliding close to 21% on Friday morning.</li>



<li>Intel (NASDAQ:<a href="https://investorplace.com/stock-quotes/intc-stock-quote/">INTC</a>) stock is falling over 20% after releasing its <a href="https://www.theverge.com/2024/8/1/24210656/intel-is-laying-off-over-10000-employees-and-will-cut-10-billion-in-costs">Q2 earnings report</a>.</li>



<li>Smith Micro Software (NASDAQ:<a href="https://investorplace.com/stock-quotes/smsi-stock-quote/">SMSI</a>) shares are decreasing more than 19% with its <a href="https://seekingalpha.com/article/4709513-smith-micro-software-inc-smsi-q2-2024-earnings-call-transcript">latest earnings report</a>.</li>



<li>GraniteShares 2x Long AMZN Daily ETF (NASDAQ:<a href="https://investorplace.com/stock-quotes/amzz-stock-quote/">AMZZ</a>) stock is slipping over 17%.</li>



<li>Snap (NYSE:<a href="https://investorplace.com/stock-quotes/snap-stock-quote/">SNAP</a>) shares close out our pre-market stock movers down more than 17% <a href="https://www.cnbc.com/2024/08/01/snap-shares-plunge-over-20percent-af.html">on weak guidance</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-aug-2nd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

The latest announcement is out from Vaccinex (VCNX). Vaccinex, Inc. has announced new insights from its SIGNAL-AD Phase 1b/2 trial assessing the pe...

Vaccinex Provides Update on Alzheimer's Treatment Trial

Vaccinex says Alzheimer's candidate buoyed by additional early-stage data

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Vaccinex (NASDAQ:<a href="https://investorplace.com/stock-quotes/vcnx-stock-quote/">VCNX</a>) just reported results for the second quarter of 2024.<ul><li>Vaccinex reported earnings per share of -$3.10.</li><li>The company reported revenue of $232,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/vcnx-stock-earnings-vaccinex-for-q2-of-2024/">VCNX Stock Earnings: Vaccinex Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

VCNX Stock Earnings: Vaccinex Reported Results for Q2 2024

An announcement from Vaccinex ( ($VCNX) ) is now available. Chrystyna Bedrij Stecyk has abruptly resigned as a director of Vaccinex, Inc., effectiv...

Vaccinex Director Chrystyna Bedrij Stecyk Abruptly Resigns

Vaccinex exercises warrants for proceeds of $6.2M

ADGM

AGBA

AMBI

AMZZ

BIIB

CERO

CGTX

CONN

COOT

CPTN

CREV

ESAIY

ESALF

ESLA

GNLN

INVO

LGVN

LIPO

LUXH

NTBL

NUWE

PAPL

PHIO

SMSI

TIVC

VERO

VTVT

YIBO

Press Releases

Vaccinex, Inc. Announces Reverse Stock Split

Contracts

Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology

Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Vaccinex Reports 2023 Financial Results and Provides Corporate Update

Financing

Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update

Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer's Disease

Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer's Disease at the Alzheimer's Association International Conference, Philadelphia, July 31, 2024

Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer's Disease

Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development Partnership

Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds

ABVC BioPharma

Alzamend Neuro

BioCardia

BioVie

Bionomics Limited - American Depository Shares

Bionomics

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

Carmell

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Eterna Therapeutics

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

Mustang Bio

Moleculin Biotech

Molecular Templates

NuCana

Organovo Holdings

Portage Biotech

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Soligenix

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Virios Therapeutics

Viracta Therapeutics, Inc. - Common Stock

Viracta Therapeutics

Xenetic Biosciences

Exicure

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Vaccinex

Vaccinex (VCNX) Forecast

Vaccinex (NASDAQ:VCNX) Stock, Quote.Headers.trade-ideas